Money
Filter News
Found 60,138 articles
-
Theranos fit in with the opaque culture of Silicon Valley, which allowed it to thrive and amass a fortune without delivering anything, book argues.
-
Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million up Front and $280 Millio...
11/15/2018
Boehringer Ingelheim and Epizyme signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million. -
Arena Pharmaceuticals Snags $800 Million from United Therapeutics for a Phase III PAH Drug
11/15/2018
United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag. -
Cadent Therapeutics secured $40 million to advance its lead program, CAD-1883.The company also struck a deal with Novartis to develop NMDA modulators.
-
Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline of Novel Therapies for Movement and Cognitive Disorders
11/15/2018
Supports Near-term Initiation of Phase 2 Essential Tremor and Spinocerebellar Ataxia Trials
-
NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
11/15/2018
NeuroVive Pharmaceutical AB announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova, Sweden's innovation agency, and the Swelife call, for intensified development in the NVP015 project, the goal of which is to advance the candidate compound NV354 to clinical studies.
-
Debbie's Dream Foundation: Curing Stomach Cancer Raises Nearly $50,000 at the 4th Annual Dream BIG Legacy Luncheon
11/15/2018
Guests gathered to raise funds for stomach cancer research and honor the legacy of late DDF Founder Debbie Zelman
-
Gimv invests in Belgian biotech company Camel-IDS, to support its unique radio-immunotherapy platform
11/15/2018
Camel-IDS, a Brussels-based company developing cancer-targeted radiopharmaceuticals today announced the completion of a series-A financing round, whereby the company secured funding of EUR 37 million
-
Khiron Life Sciences Announces Completion of Warrant Acceleration
11/15/2018
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated medical cannabis company with its core operations in Colombia, is pleased to announce that the Company has received $14,007,000 from the exercise of warrants of which the expiry date was accelerated to November 14, 2018 (the "Warrants"), as previously announced on October 25, 2018.
-
Puration Inc Announces 1:5 Nouveau Stock Dividend Declaration
11/15/2018
Puration, Inc. (USOTC: PURA) ("PURA") today announced that Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) ("NOUV") has formally declared a 1:5 stock dividend whereby NOUV common stock will be issued to the shareholders of PURA at a ratio of one NOUV
-
Gordon and Betty Moore Foundation Announces 2018 Moore Inventor Fellows
11/15/2018
Gordon Moore’s childhood passion for chemistry led him to a path of scientific invention that changed the world.
-
Rite Aid Foundation Donates $150,000 to Assist Wildfire Relief Efforts in California
11/15/2018
Donations will support local American Red Cross chapters, North Valley Community Foundation and Los Angeles Fire Department Foundation
-
AVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA®
11/15/2018
The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® as a first line treatment of adult patients with advanced renal cell carcinoma
-
NIH $1.4M grant supports study into precision bioelectronic medicine
11/15/2018
Feinstein Institute for Medical Research Professor Larry Miller, MD, has received a one-year, $1.4 million grant from the National Institutes of Health (NIH) to develop and test a non-invasive method that accesses nerves in the chest and abdomen.
-
Trovagene, Inc. Receives Positive Nasdaq Listing Decision
11/15/2018
The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market, in particular the $1.00 bid price requirement.
-
Peraton Awarded $243M Space Communications Network Services Contract Extension
11/15/2018
Award reaffirms Peraton’s 30-year partnership supporting NASA missions
-
Aspect Biosystems Receives $2.7M Investment from the Government of Canada
11/15/2018
Aspect Biosystems, a leader in the field of 3D bioprinting and tissue engineering, has received $2.7 million from the Government of Canada’s Western Innovation (WINN) Initiative. WINN has funded 17 projects in British Columbia this year, with total project funding of nearly $20 million.
-
RenalytixAI Raises $29 Million to Commercialize AI-Enabled Clinical Diagnostic Solutions for Kidney Disease
11/15/2018
Solutions to Improve Detection, Management and Treatment of Kidney Disease, Which Impacts More Than 850 Million Globally
-
Chicago-based AbbVie just announced new data for its Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.
-
AstraZeneca Continues to Divest Products, Sells Rights to RSV Drug to Sobi for $1.5 Billion
11/14/2018
Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion.